March 12, 2018
Corbus Pharmaceuticals (NASDAQ: CRBP) a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 31, 2018
Corbus Pharmaceuticals (NASDAQ: CRBP) a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that...
December 22, 2017
Corbus Pharmaceuticals Holdings announced the start of their phase 2 clinical study of anabasum, treating systemic lupus erythematosus.
December 14, 2017
Corbus Pharmaceuticals Holdings announced it started their Phase 3 study for the efficacy and safety of anabasum in the treatment...
November 27, 2017
Corbus Pharmaceuticals announced it received a patent from the US Patent and Trademark Office covering the use of pharmaceutical compositions...
November 8, 2017
Corbus Pharmaceuticals Holdings released their financial report for the third quarter of 2017.
October 31, 2017
Corbus Pharmaceuticals Holdings received a patent confirmation for their claim of using pharmaceutical compositions comprising anabasum.